Japanese clear Novartis' Gilenya, Vertex's hep C drug

Japanese regulators approved two important new drugs: Novartis's Gilenya, the first oral multiple sclerosis treatment, and Vertex Pharmaceuticals's Telavic, the hepatitis C treatment sold as Incivek in the U.S. and developed for Japan in partnership with Mitsubishi Tanabe Pharma. Novartis release | Release

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

The countdown to the FDA's first coronavirus vaccine hearing has begun, and new agency documents outline an agenda for the Thursday confab.

Black Americans’ confidence in COVID-19 vaccines is dropping, with only 43% saying they will get a vaccine once it's out—down 22 points since August.